← All trials
NCT04873570
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 28, 2021
- Primary completion
- Jun 8, 2021
- Completion date
- Jun 10, 2021
- First posted
- May 5, 2021
- Last posted
- Jun 15, 2021
- Enrollment
- 38
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of KarachiLead sponsor
- University of KarachiReponsible party - principal investigator
- University of KarachiCollaborator
- SAMI Pharmaceutical, Karachi PakistanCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.